We are excited to announce the rebranding of Cryoport Systems & affiliated companies, reflecting the significant changes that transformed Cryoport Systems into a robust platform of temperature-controlled supply chain management solutions. Explore: https://t.co/uxftwjwopG $CYRX

Cryoport, Inc. $CYRX Q3 2025 results: 745 global clinical trials supported as of September 30, including 83 in Phase 3. We also supported 19 commercial therapies and opened a new supply chain center in Paris.

Cryoport, Inc. $CYRX Q3 2025 earnings showed continued growth in Life Sciences Services, up 16% year-over-year. BioStorage/BioServices revenue rose 21%, and new dry vapor shippers with integrated monitoring were introduced.

Cryoport, Inc. $CYRX released Q3 2025 earnings today. Total revenue grew 15% year-over-year, driven partly by a 36% increase from our support of commercial cell and gene therapies. Full details:

Today, Cryoport Inc. $CYRX will release its Q3 2025 financial results after market close. Following the release, our leadership team will host a Q&A call at 5pm ET. A Q3 2025 Review document will be available by 4:15 p.m. ET. For details, please visit: https://t.co/wSrA1nUGBj

Cryoport Systems, a Cryoport, Inc. $CYRX company, is now ISO 21973 certified, the first global supply chain solutions company to earn this distinction for transporting therapeutic cells. Learn more: https://t.co/qOxYGahKXG

Cryoport, Inc. $CYRX will announce our Q3-25 financial results next Tues Nov 4 after U.S. markets close. Following the release, we invite investors to join a Q&A conference call at 5pm ET. For details, please visit https://t.co/Ybz4XXXvdH

Encouraging news for fertility care that could expand access and drive market growth. Cryoport $CYRX enables this progress with secure, temperature-controlled logistics that safeguard reproductive materials worldwide. https://t.co/Ar1QSQRDLQ

Cryoport, Inc. $CYRX is proud to announce the launch of MVE Biological Solutions’ real-time condition monitoring systems for its MVE SC 4/2 V and 4/3 V series dewars, both powered by Tec4Med, another Cryoport company. Read the press release: https://t.co/K4K2u8MNoK

Cryoport $CYRX is proud to announce the launch its newest Global Supply Chain Center in France. Strategically located in Paris (Louvres), this state-of-the-art facility provides end-to-end, temperature-controlled supply chain solutions under one roof, https://t.co/MT9hcrgeFO

Congratulations to Cryoport ($CYRX) client ExCellThera on the approval of Zemcelpro® by the European Commission (EC). More info here:

Cryoport ($CYRX) is advancing the future of life sciences logistics through our strategic partnership with DHL. Gas World covers DHL’s acquisition of CRYOPDP, a move that strengthens global cold chain solutions for CGT, biopharma, and clinical trials.

Cryoport ($CYRX) and DHL's partnership continues to make waves! Freight Waves reports on DHL’s $195M acquisition of CRYOPDP, a move that strengthens global pharma logistics and expands support for CGT and life sciences.

Cryoport ($CYRX) and DHL’s strategic partnership is shaping the future of pharma logistics! Air Cargo News highlights how DHL’s acquisition of CRYOPDP strengthens global supply chains for life sciences.

Cryoport ($CYRX) and DHL's partnership continues to make headlines! CAAS covers DHL’s acquisition of CRYOPDP and how this strengthens global life sciences logistics. Together, we’re enhancing supply chain solutions.

Cryoport ($CYRX) and @DHL’s strategic partnership is a major step in Advancing the Future of Medicine™. With DHL’s acquisition of CRYOPDP, we’re expanding innovation, strengthening supply chains, and positioning for long-term success in life science. https://t.co/Jy35VQPJCV

https://t.co/K6wgYQ4jKF covers @DHL’s acquisition of CRYOPDP and its strategic partnership with Cryoport ($CYRX) to expand life sciences logistics worldwide. Together, we’re strengthening the global supply chain to Advance the Future of Medicine™.

Morningstar Dow Jones covers @DHL’s acquisition of CRYOPDP and its strategic partnership with Cryoport ($CYRX). This milestone strengthens global life sciences logistics, supporting cell and gene therapy, biopharma, and clinical trials.

A strong, scalable supply chain is key to the future of advanced therapies. Cryoport’s ($CYRX) partnership with @DHL and their acquisition of CRYOPDP enhance global logistics for cell and gene therapy, biopharma, and clinical trials. Learn more:

Cryoport’s ($CYRX) strategic partnership with @DHL continues to gain attention. https://t.co/K6wgYQ4jKF covers DHL’s acquisition of CRYOPDP and the impact it will have on strengthening global life sciences logistics. Exciting growth ahead!

Cryoport ($CYRX) and @DHL’s strategic partnership, including the acquisition of CRYOPDP, is making headlines. Reuters highlights how this move strengthens global pharma logistics and expands life sciences supply chain capabilities. Read more: